CBM Cambrex Corp

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐

Check the appropriate box:

CAMBREX CORPORATION

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

Employee Video - Script

Dear Cambrex Experts and Valued Colleagues,

As you have seen from the announcement earlier today, I am excited to report that Cambrex and Permira have signed a definitive agreement in which Permira will acquire all outstanding shares of Cambrex Corporation.

On behalf of the entire executive team, we are extremely pleased to have reached an agreement with Permira. It is my intention today to share with you some more details.

First and foremost it is our firm belief that this agreement is in the best interests of everyone at Cambrex…our investors, our customers and importantly, you, our valued employees.

Secondly, we are proud to be working with Permira. Permira is a global investment firm and has a history of investing in growing companies and providing them with the resources to accelerate growth. They are well versed in the drug substance and drug product industry and have made a number of strategic investments in the pharmaceutical services industry that we see as complementary to Cambrex. With our new partnership we expect even more opportunities for growth by being part of Permira’s strategic network as well as access to additional capital investment to help expand into new technologies and markets and further enhance our world class facilities.

Finally, I wanted to address how it affects you, our valued employees. With any new partnership, it is quite normal to be concerned or worried during a period of change or uncertainty. When I look back over the last 11 years that I have had the privilege to be your Chief Executive Officer at Cambrex, I cannot remember a time when we were not experiencing change or uncertainty. From our acquisition of PharmaCore and our period of record growth and emergence as one of the fastest growing CDMOs in the industry, to the recent acquisitions of Halo and Avista and our evolution to an end-to-end CDMO, we have been constantly changing and evolving.

Our success during this period has been due to the commitment and passion for excellence of our global team of employees. So continue to serve our customers with the world class service they expect from us. Continue to seek new opportunities. Continue to be better than and one step ahead of the competition. Continue to be part of the world’s best small molecule company. And continue to be the experts our customers enjoy working with. In other words, it is business as usual.

I am excited about the future and I know you will share that excitement as we go forward. In the meantime, have a great summer and I look forward to getting back to you with more updates over the coming few months.

Cautionary Language Concerning Forward-Looking Statements

Information set forth in this communication, including financial estimates and statements as to the expected timing, completion and effects of the proposed transaction between Cambrex and Permira, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by the fact that they use words such as “may,” “will,” “could,” “should,” “would,” “expect,” “anticipate,” “intend,” “estimate,” “believe” or similar expressions. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. These forward-looking statements are subject to risks and uncertainties, and actual results might differ materially from those discussed in, or implied by, the forward-looking statements. Such forward-looking statements may include, but are not limited to, statements about the anticipated benefits of the merger, including future financial and operating results, expected synergies and cost savings related to the merger, the plans, objectives, expectations and intentions of Cambrex, Permira and the combined company, the expected timing of the completion of the merger, and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of the management of Cambrex or Permira, as applicable, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, and actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Neither Cambrex nor Permira, nor any of their respective directors, executive officers or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur. Among the

2

risks and uncertainties that could cause actual results to differ from those described in the forward-looking statements are the following: the occurrence of any event, change or other circumstances that could give rise to the termination of the merger Agreement, the risk that Cambrex’s stockholders may not adopt the merger Agreement, the risk that the necessary regulatory approvals may not be obtained or may be obtained subject to conditions that are not anticipated, risks that any of the closing conditions to the merger may not be satisfied or waived in a timely manner, risks related to disruption of management time from ongoing business operations due to the merger, the effect of the announcement of the merger on the ability of Cambrex to retain customers and retain and hire key personnel and maintain relationships with its suppliers and other business partners, and on their operating results and businesses generally, the risk that potential litigation in connection with the merger may affect the timing or occurrence of the merger or result in significant costs of defense, indemnification and liability and transaction costs.

The forward-looking statements are based on the beliefs and assumptions of Company management and the information available to Company management as of the date of this report. Cambrex cautions investors not to place undue reliance on expectations regarding future results, levels of activity, performance, achievements or other forward-looking statements. The information contained in this document is provided by Cambrex as of the date hereof, and, unless required by law, Cambrex does not undertake and specifically disclaims any obligation to update these forward-looking statements contained in this document as a result of new information, future events or otherwise.

Discussions of additional risks and uncertainties are and will be contained in Cambrex’s filings with the SEC, including the “Risk Factors” sections of Cambrex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018. You can obtain copies of Cambrex’s filings with the SEC for free at the SEC’s website (www.sec.gov).

Certain Information Regarding Participants

Cambrex and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Cambrex’s directors and executive officers is available in Cambrex’s Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on February 13, 2019, and in its proxy statement for the 2019 Annual Meeting, which was filed with the SEC on March 12, 2019. To the extent holdings of Company securities have changed since the amounts printed in the proxy statement for the 2019 Annual Meeting, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available. These documents will be available free of charge from the sources indicated below.

Important Information and Where to Find It

In connection with the proposed transaction, Cambrex will file with the SEC a proxy statement with respect to a special meeting of Cambrex’s stockholders to approve the transaction. The definitive proxy statement will be mailed to the stockholders of Cambrex. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CAMBREX AND THE TRANSACTION.

Investors and security holders will be able to obtain these materials, when they are available, and other relevant documents filed with the SEC free of charge at the SEC’s website, www.sec.gov. In addition, copies of the proxy statement, when they become available, may be obtained free of charge by accessing Cambrex’s website at www.cambrex.com or by contacting Cambrex’s investor relations department by email at stephanie.lafiura@cambrex.com.

3

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

4